Canbex Therapeutics Ltd. (Canbex) announced today that it has received a Translation Award of up to 1.75 million ($2.8 million) from the Wellcome Trust to support development of a drug for the treatment of the debilitating muscle spasms associated with multiple sclerosis and potentially other disorders.
The award will facilitate further preclinical development of Canbex's VSN series of compounds and the progression into clinical trials. It is anticipated that a Phase I trial of lead compound VSN16R could begin in December 2012.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1743